

# Biologics Market Growth Is Boosted With Increasing Investments For Life Science Research

*The Business Research Company's  
Biologics Market 2022 – Opportunities  
And Strategies – Global Forecast To 2030*

LONDON, GREATER LONDON, UK, July 5, 2022 /EINPresswire.com/ --

Increasing funding from public and private organizations for the development of vaccines against COVID-19 is expected to drive the market in the forecast period. The large amount of funding from the public and private organizations


accelerates the process of drug development and supports research of new drugs. For instance, In 2020, MTF Biologics which is a global non-profit organization has awarded over \$1 million in funding to 11 research studies across the US through its 2020 Extramural Research Grants Program. According to the biologics industry analysis, increasing public-private funding for life science research will enhance the research and development which will drive the growth of the [biologics market](#).

The biologics market size is expected to grow from \$253.41 billion in 2020 to \$420.55 billion in 2025 at a rate of 10.7%. The biologics market share is then expected to grow at a CAGR of 9.6% from 2025 and reach \$664.74 billion in 2030.

Read more on the Global Biologics Market Report

<https://www.thebusinessresearchcompany.com/report/biologics-market>

The US Food and Drug Administration (FDA) has revised its regulations to eliminate outdated biologics requirements, thus allowing drug manufacturers to employ new manufacturing technologies and testing capabilities, which is one of the key biologics market trends. Standard preparations (standard solutions containing a precisely known concentration of an element), which help to ensure safety, purity and potency of biologics, can now be obtained from sources other than the FDA's Center for Biologics Evaluation and Research (CBER), or can be developed



internally by the biologics license applicant. The FDA has also removed a rule (Section 610.21 of FDA code) which specifies minimal potency limits to be met for certain antibodies and antigens. In addition, the FDA is also updating regulations (Section 610.53 of FDA code) regarding storage periods and storage conditions for biologics.

Major players covered in the global biologics market are Merck & Co., Inc., AbbVie Inc., F. Hoffmann-La Roche AG, Johnson & Johnson, Pfizer Inc.

TBRC's global biologics market report is segmented by type into monoclonal antibodies (MAbs), therapeutic proteins, vaccines, by distribution channel into hospital pharmacies, retail pharmacies/ drug stores, others, by route of administration into oral, parenteral, others, by drug classification into branded drugs, generic drugs, by mode of purchase into prescription-based drugs, over-the-counter drugs.

[Biologics Market 2022](#) - By Type (Therapeutic Proteins, Monoclonal Antibodies ((MAbs), Vaccines), By Route Of Administration (Oral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription Drugs, Over-The-Counter (OTC) Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2030 is one of a series of new reports from The Business Research Company that provides a biologics market overview, forecast biologics market size and growth for the whole market, biologics market segments, geographies, biologics market trends, biologics market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request for a Sample of the Global Biologics Market Report

<https://www.thebusinessresearchcompany.com/sample.aspx?id=792&type=smp>

Not what you were looking for? Here is a list of similar reports by The Business Research Company:

Bi-Specific MAbs Global Market Report 2022 – By Type (Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597), By Product Type (In Vivo, In Vitro), By Indication (Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases), By End Use (Hospitals, Research Institutes) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report>

Oral Biologics & Biosimilar Drugs Global Market Report 2022 – By Therapy (Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors), By Disease (Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global->

## [market-report](#)

Vaccines Global Market Report 2022 – By Type (Anti-Infective Vaccines, Autoimmunity, Others (Cancer And Others)), By Technology (Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines), By Route of Administration (Intramuscular (IM), Subcutaneous (SC), Oral, Others), By Valance (Monovalent, Multivalent), By Distribution Channel (Institutional Sale, Hospital Pharmacies, Retail Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report>

### About [The Business Research Company?](#)

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: [info@tbrc.info](mailto:info@tbrc.info)

Check out our:

LinkedIn: <https://bit.ly/3b7850r>

Twitter: <https://bit.ly/3b1rmjS>

YouTube: [https://www.youtube.com/channel/UC24\\_fl0rV8cR5DxICpgmyFQ](https://www.youtube.com/channel/UC24_fl0rV8cR5DxICpgmyFQ)

Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

[info@tbrc.info](mailto:info@tbrc.info)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/579820558>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors

try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.